# US 2020/0392192 A1 · Anti-viral proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392192 A1
- Document ID: US20200392192A1
- Status: Published application
- Kind: A1
- Application number: 16/971,020
- Filed: 2019-03-29
- Published: 2020-12-17
- Earliest claimed: 2018-04-24
- Assignees: Ophiuchus Medicine Inc.
- Applicants: Ophiuchus Medicine Inc
- Inventors: Yasser Salim HASSAN; Sherry OGG
- Web page: https://patentgrep.com/patent/US20200392192A1

## CPC

- A61P 31/12: Antivirals
- C07K 14/415: from plants
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 31/20: for DNA viruses
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

It is provided an anti-viral fusion protein comprising the structure of X-Y-Z, wherein X is a full length Ricin A chain (RTA) or a variant thereof, Y is absent or a linker and Z is a full length Pokeweed antiviral proteins (PAP) or a variant thereof. Particularly, it is provided an optimized protein ricin A chain mutant-Pokeweed antiviral protein isoform 1 from leaves (RTAM-PAP1).

## Claims

### Claim 1

An anti-viral fusion protein comprising the structure:
X-Y-Z
wherein X is a full length Ricin A chain (RTA) or a variant thereof, Y is absent or a linker and Z is a full length Pokeweed antiviral protein (PAP) or a variant thereof.

### Claim 2 (depends on 1)

The anti-viral fusion protein of claim 1, wherein Z is the Pokeweed Antiviral Protein from Leaves (PAP1).

### Claim 3 (depends on 2)

The anti-viral fusion protein of claim 2, wherein PAP1 comprises amino acids 296-556 of SEQ ID NO: 2.

### Claim 4 (depends on 1)

The anti-viral fusion protein of claim 1, wherein the linker is chemical linker or a polylinker.

### Claim 5 (depends on 1)

The anti-viral fusion protein of claim 1, wherein the linker is a flexible linker.

### Claim 6 (depends on 5)

The anti-viral fusion protein of claim 5, wherein the flexible linker comprises amino acids 275-295 of SEQ ID NO: 2.

### Claim 7 (depends on 1)

The anti-viral fusion protein of claim 1, wherein X is a mutant of RTA (RTAM).

### Claim 8 (depends on 7)

The anti-viral fusion protein of claim 7, wherein RTAM comprises amino acids 8-274 of SEQ ID NO: 2.

### Claim 9 (depends on 1)

The anti-viral fusion protein of claim 1, comprising the amino acid sequence of SEQ ID NO: 1.

### Claim 10 (depends on 1)

The anti-viral fusion protein of claim 1, comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 11 (depends on 1)

The anti-viral fusion protein of claim 1, for treating a viral infection.

### Claim 12 (depends on 11)

The anti-viral fusion protein of claim 11, wherein the viral infection is from the Hepatitis B virus (HBV), Hepatitis C virus (HCV), Kaposi Sarcoma-Associated Herpesvirus (KSHV), Merkel Cell Polyomavirus (MCV). Human T-Cell Lymphotropic Virus Type 1 (HTLV-1), Epstein-Barr Virus (EBV), human immunodeficiency virus-1 (HIV-1), Zika virus, Japanese encephalitis virus, Herpes Simplex, Poliovirus, Influenza virus, coronavirus or papillomavirus.

### Claim 13 (depends on 11)

The anti-viral fusion protein of claim 11, wherein the viral infection causes liver cancer, Kaposi sarcoma, skin cancer, Merkel cell carcinoma, leukemia, lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphomas, Post-transplant lymphoproliferative disorder, respiratory disease or Leiomyosarcoma.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 1)

The anti-viral protein of claim 1, wherein said fusion protein is active against plant, animal or human pathogens.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A composition comprising the fusion protein of claim 1 and a carrier.

### Claim 19 (depends on 1)

A method of treating a viral infection in a patient comprising administering to said patient a fusion protein of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the viral infection is from the Hepatitis B virus (HBV), Hepatitis C virus (HCV), Kaposi Sarcoma-Associated Herpesvirus (KSHV), Merkel Cell Polyomavirus (MCV). Human T-Cell Lymphotropic Virus Type 1 (HTLV-1), Epstein-Barr Virus (EBV), human immunodeficiency virus-1 (HIV-1), Zika virus, Influenza virus, coronavirus or papillomavirus.

### Claim 21 (depends on 19)

The method of claim 19, wherein the viral infection causes liver cancer, Kaposi sarcoma, skin cancer, Merkel cell carcinoma, leukemia, lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphomas, Post-transplant lymphoproliferative disorder, respiratory disease or Leiomyosarcoma.

### Claim at position 21

22-23. (canceled)

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method of any one of claims 19-23, wherein said fusion protein is active against plant, animal or human pathogens.

### Claim at position 23

25-30. (canceled)
